EP2328931 - ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 20.06.2014 Database last updated on 02.09.2024 | Most recent event Tooltip | 22.06.2018 | Lapse of the patent in a contracting state New state(s): MK | published on 25.07.2018 [2018/30] | Applicant(s) | For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, IN 46285 / US | [2011/23] | Inventor(s) | 01 /
LEUNG, Donmienne, Doen, Mun Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | 02 /
LUAN, Peng 1869 Altamont Circle Livermore California 94551 / US | 03 /
TANG, Ying Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | 04 /
WITCHER, Derrick, Ryan Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | 05 /
YACHI, Pia, Pauliina Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2013/33] |
Former [2011/27] | 01 /
LEUNG, Donmienne, Doen, Mun Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | ||
02 /
LUAN, Peng 1869 Altamont Circle Livermore California 94551 / US | |||
03 /
TANG, Ying Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | |||
04 /
WITCHER, Derrick, Ryan Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | |||
05 /
YACHI, Pia, Pauliina Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | |||
Former [2011/23] | 01 /
LEUNG, Donmienne, Doen, Mun Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | ||
02 /
LUAN, Peng Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | |||
03 /
TANG, Ying Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | |||
04 /
WITCHER, Derrick, Ryan Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | |||
05 /
YACHI, Pia, Pauliina Eli Lilly And Company Lilly Corporate Center Indianapolis, IN 46285 / US | Representative(s) | O'Connor, David, et al Eli Lilly and Company Limited Lilly research Centre Erl Wood Manor Windlesham, Surrey GU20 6PH / GB | [2013/08] |
Former [2012/03] | Burnside, Ivan John, et al Eli Lilly and Company Limited Lilly Research Centre Erl Wood Manor Sunninghill Road Windlesham Surrey GU20 6PH / GB | ||
Former [2011/23] | Commander, Paul Martin Brial Eli Lilly and Company Limited Lilly Research Centre Erl Wood Manor Sunninghill Road GB-Windlesham, Surrey GU20 6PH / GB | Application number, filing date | 09790908.9 | 29.07.2009 | [2011/23] | WO2009US52044 | Priority number, date | US20080086557P | 06.08.2008 Original published format: US 86557 P | [2011/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010017070 | Date: | 11.02.2010 | Language: | EN | [2010/06] | Type: | A1 Application with search report | No.: | EP2328931 | Date: | 08.06.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.02.2010 takes the place of the publication of the European patent application. | [2011/23] | Type: | B1 Patent specification | No.: | EP2328931 | Date: | 14.08.2013 | Language: | EN | [2013/33] | Search report(s) | International search report - published on: | EP | 11.02.2010 | Classification | IPC: | C07K16/26, G01N33/577, A61K39/395, A61P7/06 | [2011/23] | CPC: |
C07K16/26 (EP,US);
C07K16/18 (KR);
A61K39/395 (KR);
A61P7/06 (EP);
G01N33/577 (KR);
G01N33/74 (EP,US);
C07K2317/34 (EP,US);
C07K2317/565 (EP,US);
C07K2317/567 (EP,US);
C07K2317/92 (EP,US)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2011/23] | Extension states | AL | 07.03.2011 | BA | 07.03.2011 | RS | 07.03.2011 | Title | German: | SELEKTIVE ANTI-HEPCIDIN-25-ANTIKÖRPER UND ANWENDUNGEN DAVON | [2011/23] | English: | ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF | [2011/23] | French: | ANTICORPS SÉLECTIFS ANTI-HEPCIDINE-25 ET LEURS UTILISATIONS | [2011/23] | Entry into regional phase | 07.03.2011 | National basic fee paid | 07.03.2011 | Designation fee(s) paid | 07.03.2011 | Examination fee paid | Examination procedure | 07.03.2011 | Examination requested [2011/23] | 07.04.2011 | Amendment by applicant (claims and/or description) | 26.10.2011 | Despatch of a communication from the examining division (Time limit: M04) | 01.03.2012 | Reply to a communication from the examining division | 04.03.2013 | Communication of intention to grant the patent | 28.06.2013 | Fee for grant paid | 28.06.2013 | Fee for publishing/printing paid | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 26.10.2011 | Opposition(s) | 15.05.2014 | No opposition filed within time limit [2014/30] | Fees paid | Renewal fee | 16.07.2011 | Renewal fee patent year 03 | 10.07.2012 | Renewal fee patent year 04 | 28.06.2013 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 29.07.2009 | BG | 14.08.2013 | CY | 14.08.2013 | CZ | 14.08.2013 | EE | 14.08.2013 | HR | 14.08.2013 | LT | 14.08.2013 | LV | 14.08.2013 | MC | 14.08.2013 | MK | 14.08.2013 | MT | 14.08.2013 | RO | 14.08.2013 | SI | 14.08.2013 | SK | 14.08.2013 | SM | 14.08.2013 | IS | 14.12.2013 | [2018/30] |
Former [2016/32] | HU | 29.07.2009 | |
BG | 14.08.2013 | ||
CY | 14.08.2013 | ||
CZ | 14.08.2013 | ||
EE | 14.08.2013 | ||
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
MC | 14.08.2013 | ||
MT | 14.08.2013 | ||
RO | 14.08.2013 | ||
SI | 14.08.2013 | ||
SK | 14.08.2013 | ||
SM | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2016/28] | BG | 14.08.2013 | |
CY | 14.08.2013 | ||
CZ | 14.08.2013 | ||
EE | 14.08.2013 | ||
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
MC | 14.08.2013 | ||
MT | 14.08.2013 | ||
RO | 14.08.2013 | ||
SI | 14.08.2013 | ||
SK | 14.08.2013 | ||
SM | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2016/22] | CY | 14.08.2013 | |
CZ | 14.08.2013 | ||
EE | 14.08.2013 | ||
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
MC | 14.08.2013 | ||
RO | 14.08.2013 | ||
SI | 14.08.2013 | ||
SK | 14.08.2013 | ||
SM | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2016/21] | CY | 14.08.2013 | |
CZ | 14.08.2013 | ||
EE | 14.08.2013 | ||
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
MC | 14.08.2013 | ||
RO | 14.08.2013 | ||
SI | 14.08.2013 | ||
SK | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2014/23] | CY | 14.08.2013 | |
CZ | 14.08.2013 | ||
EE | 14.08.2013 | ||
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
RO | 14.08.2013 | ||
SI | 14.08.2013 | ||
SK | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2014/22] | CY | 14.08.2013 | |
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
RO | 14.08.2013 | ||
SI | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2014/18] | CY | 14.08.2013 | |
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
SI | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2014/12] | CY | 17.07.2013 | |
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
LV | 14.08.2013 | ||
SI | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2014/10] | CY | 17.07.2013 | |
HR | 14.08.2013 | ||
LT | 14.08.2013 | ||
IS | 14.12.2013 | ||
Former [2014/09] | HR | 14.08.2013 | |
LT | 14.08.2013 | ||
Former [2014/08] | LT | 14.08.2013 | Cited in | International search | [XA]US2006019339 (LAUTH XAVIER [US], et al) [X] 1-6,9-10,12-19,31 * paragraph [0094] - paragraph [0097]; claims 8-20 * [A] 7-8,11,20-30; | [X]US2007224186 (KULAKSIZ HASAN [DE], et al) [X] 1-6,9-10 * page 78; claims 1-23 *; | [XPI]WO2008097461 (AMGEN INC [US], et al) [XP] 1-6,9-10,12-22,28-31 * paragraph [0408]; examples 10-20,30-32; tables 3,6,7 * [I] 7-8,11,23-27; | [IP]WO2009027752 (HELLENIC PASTEUR INST [GR], et al) [IP] 1-31 * page 26, line 17 - page 27, line l; claims 23-27 *; | [XPI]WO2009044284 (INST NAT SANTE RECH MED [FR], et al) [XP] 1-6,9-10,12-22,28-31 * page 11; examples 1-3; claims 1-5,12-14 * [I] 7-8,11,23-27; | [XPI]WO2009058797 (LILLY CO ELI [US], et al) [XP] 1-6,9-10,12-22,28-31 * examples 2-6; claims 1-44; tables 5,6,9 * [I] 7-8,11,23-27; | [A] - KEMNA ERWIN H J M ET AL, "Hepcidin: from discovery to differential diagnosis", HAEMATOLOGICA, FONDAZIONE FERRATA STORTI, ROME, IT, (20080101), vol. 93, no. 1, ISSN 0390-6078, pages 90 - 97, XP002502643 [A] 1-31 * the whole document * DOI: http://dx.doi.org/10.3324/HAEMATOL.11705 | by applicant | WO2005005604 | US2006019339 | US2007224186 | US2008213277 | - KEMNA, E.H. ET AL., HAEMATOLOGICA, (2008), vol. 93, no. 1, pages 90 - 97 | - ROE M.A. ET AL., BR J NUTR., (2007), vol. 97, pages 544 - 549 | - LUUKKONEN S.; PUNNONEN K., CLIN CHEM LAB MED., (2006), vol. 44, pages 1361 - 1362 | - GUTIERREZ, J.A. ET AL., BIOTECHNIQUES, (2005), vol. 38, pages S13 - S17 | - MURPHY ET AL., BLOOD, (2007), vol. 110, pages 1048 - 1054 | - KEMNA, E.H. ET AL., CLIN. CHEM., (2007), vol. 53, pages 620 - 628 | - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315 | - JAYASENA, S.D., CLIN. CHEM., (1999), vol. 45, pages 1628 - 1650 | - FELLOUSE, F.A. ET AL., J. MOL. BIOL., (2007), vol. 373, no. 4, pages 924 - 940 |